Pilot study of raltegravir augmentation on persistent central nervous system (CNS) immunoactivation in treated HIV-1 patients

Trial Profile

Pilot study of raltegravir augmentation on persistent central nervous system (CNS) immunoactivation in treated HIV-1 patients

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2015

At a glance

  • Drugs Raltegravir (Primary) ; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Feb 2010 Substudy results assessing viraemia in cerebrospinal fluid presented at the 17th Conference on Retroviruses and Opportunistic Infections.
    • 27 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top